Clinical Trials Logo

Cystitis clinical trials

View clinical trials related to Cystitis.

Filter by:

NCT ID: NCT01997983 Completed - Clinical trials for Interstitial Cystitis

Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients

Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators believe that this study is of importance of several aspects: 1. It evaluates a new mode of bladder instillation that may bypass the drawbacks of the current instillation mode. 2. It will demonstrating safety of intravesical instillations of BTX mixed with TC-3 gel in IC patients 3. If proved effective or partially effective, this mode of treatment will serve as a basis for large feasibility study exploring its safety and efficacy aspects.

NCT ID: NCT01990898 Completed - Clinical trials for Interstitial Cystitis

Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action

CIC
Start date: November 2013
Phase: Phase 2
Study type: Interventional

This is a study for patients that have a condition called Interstitial Cystitis, also known as Painful Bladder Syndrome. Patients would have tried at least two different therapies, unsuccessfully,(eg. medications, pelvic floor physical therapy) The purpose of this research project is to study the immunosuppressive drug Cyclosporine in patients with Interstitial Cystitis to assess how well it works, what the side effects are and what is its mechanism of action. Cyclosporine is a drug that is FDA-approved to prevent organ rejection after kidney, liver, and heart transplant but is not approved by the FDA for Interstitial Cystitis. Several research studies have been published showing that Cyclosporine can improve the symptoms of Interstitial Cystitis, that it works better than a placebo ("sugar pill" or inert treatment) and that it works more effectively than Pentosan Polysulfate (Elmiron), which is an FDA approved therapy. The dose of Cyclosporine used in these studies on Interstitial Cystitis are much lower that the doses used to prevent rejection in transplant patients. Based on these studies, the American Urological Association has recently published treatment guidelines that recommend Cyclosporine therapy for Interstitial Cystitis after the failure of other more conservative therapies and medications. Nevertheless, much is not known about using Cyclosporine therapy for Interstitial Cystitis including the mechanism of action, the ideal dose, how best to monitor for side effects and in particular whether kidney damage can occur at the low doses used in these studies. In this study, to examine the mechanism of action, blood and urine samples will be collected before, during and after therapy to look at "biomarkers", chemical substances that can be associated with inflammation and tissue injury. We will also test effects of therapy on skin sensation and pain perception because the molecule which Cyclosporine binds to (calcineurin) is also found in nerves that conduct pain signals. This study is only being done at the Cleveland Clinic and will involve about 30 patients with Interstitial Cystitis.

NCT ID: NCT01985880 Completed - Clinical trials for Interstitial Cystitis

The Efficacy of Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome

Start date: November 19, 2013
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate efficacy of biomarker in patient with interstitial cystitis/painful bladder syndrome

NCT ID: NCT01969773 Completed - Clinical trials for Interstitial Cystitis

Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This study was designed in a multicenter, randomized, double-blind, placebo controlled trial to test the actual therapeutic effects of intravesical BoNTA injection. The results of this study might provide clinical evidence for a better therapeutic regimen in the treatment of IC/PBS.

NCT ID: NCT01882543 Completed - Clinical trials for Interstitial Cystitis

Efficacy and Safety of AQX-1125 in IC/BPS

LEADERSHIP
Start date: June 2013
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the effect of 6 weeks of treatment with once daily administration of AQX-1125 compared to placebo on average daily pain in subjects with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary

NCT ID: NCT01879683 Completed - Clinical trials for Chronic Interstitial Cystitis

A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions

Start date: July 2013
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate if LiRIS 400 mg is safe and tolerable when administered to women with Interstitial Cystitis with Hunner's lesions, and to evaluate any change in the bladder or in IC symptoms, following LiRIS administration.

NCT ID: NCT01861353 Completed - Clinical trials for Urinary Tract Infection

Cranberry-lingonberry Juice Started During Acute Infection in Prevention of Urinary Tract Infections in Children

Start date: May 2013
Phase: N/A
Study type: Interventional

Cranberry and cranberry-lingonberry juice prevented urinary tract infections in children and in adults in our earlier clinical trials. The preventive effect was, however, observed late in the follow-up and the next recurrence was not prevented in children. The investigators hypothesize that cranberry-lingonberry juice should be started already during the antimicrobial treatment of acute urinary tract infection in order to maximize the preventive efficacy of the juice. In addition, the investigators aim to find the explanation for the efficacy of cranberry-lingonberry juice by analyzing the concomitant changes in the chemical composition of urine and feces as well as the changes of gut microbiota.

NCT ID: NCT01849926 Completed - Clinical trials for Acute Cystitis (Excl in Pregnancy)

Ibuprofen Versus Mecillinam for Uncomplicated Cystitis

IMUTI
Start date: April 2013
Phase: Phase 4
Study type: Interventional

Although uncomplicated cystitis is considered to be a mild condition and mostly self limiting, most patients who see a doctor will be treated with antibiotics. Antibiotics are known to give a quick relief of symptoms and shorten the course of the condition by a few days. The aim of this study is to evaluate ibuprofen versus mecillinam in the treatment of uncomplicated cystitis in otherwise healthy, non-pregnant women. Our main objective is to see whether symptomatic treatment with ibuprofen is equally efficient as treatment with mecillinam in this group.

NCT ID: NCT01816646 Completed - Clinical trials for Blood And Marrow Transplantation

Intravesical Cidofovir for Hemorrhagic Cystitis

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to learn how the drug cidofovir given as 1 dose directly into the bladder is absorbed by the body. Researchers also want to measure the amount of study drug in the body at different time points. The safety and tolerability of this drug will also be studied. Cidofovir is designed to fight certain viruses by blocking the virus cells from dividing.

NCT ID: NCT01800799 Completed - Clinical trials for Urinary Tract Infection

Urinary NGF as A Biomarker for Acute Bacterial Cystitis

Start date: February 2013
Phase: N/A
Study type: Interventional

This study will enroll 30 female patients with the first time urinary tract infection (UTI), 30 female patients with recurrent UTI and 10 female without any prior history of UTI or urinary tract pathology will be invited to serve as the controls. Urine samples will be collected in the patients at baseline, 7 days after antibiotics treatment, and 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Urinalysis will be performed at each visit and urine culture will be performed at baseline and at the 2 weeks and 3 months visits. Urine samples at baseline and 3 months will be collected from the controls for comparison.